Volume 4.10 | Mar 15

Prostate Cell News 4.10 March 15, 2013
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Cod Glycopeptide with Picomolar Affinity to Galectin-3 Suppresses T-Cell Apoptosis and Prostate Cancer Metastasis
Scientists showed that a β-galactoside-binding lectin (galectin-3) that recognizes the Thomsen-Friedenreich disaccharide present on the surface of most cancer cells is involved in promoting angiogenesis, tumor-endothelial cell adhesion, and metastasis of prostate cancer cells, as well as evading immune surveillance through killing of activated T cells. [Proc Natl Acad Sci USA] Abstract

[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells
Investigators report that (S)-2, a novel hydroxamate-based histone deacetylase inhibitor, shown previously to be effective against acute myeloid leukemia cells, was also a potent inducer of apoptosis/differentiation in human prostate LNCaP and PC3 cancer cells. [PLoS One] Full Article

Probing the Interaction Forces of Prostate Cancer Cells with Collagen I and Bone Marrow Derived Stem Cells on the Single Cell Level
Adhesion of metastasizing prostate carcinoma cells was quantified for two carcinoma model cell lines LNCaP and PC3. By time-lapse microscopy and force spectroscopy researchers found PC3 cells to preferentially adhere to bone marrow-derived mesenchymal stem cells. [PLoS One] Full Article

The Proto-Oncogene ERG Is a Target of MicroRNA miR-145 in Prostate Cancer
The authors showed that the ERG 3’ untranslated region is a regulative target of miR-145 in vitro. Ectopic expression of miR-145 led to a reduction in the expression of the ERG protein. They analyzed 26 prostate cancer samples with their corresponding normal tissue. [FEBS J] Abstract

Reactive Oxygen Species Generation Inhibits Epithelial-Mesenchymal Transition and Promotes Growth Arrest in Prostate Cancer Cells
Scientists explored the pro-oxidant property of 3,9-dihydroxy-2-prenylcoumestan (pso), a dietary agent, on prostate cancer (CaP) cells. Pso greatly induced reactive oxygen species generation (more than 20-fold) that resulted in the growth inhibition of CaP cells. [Mol Carcinog] Abstract

Effect of Finasteride on Serum Levels of Androstenedione, Testosterone and Their 5α-Reduced Metabolites in Men at Risk for Prostate Cancer
Although it is known that finasteride treatment suppresses serum levels of dihydrotestosterone (DHT) and its distal metabolite, 5α-androstane-3α,17β-diol glucuronide, and increases serum testosterone levels, little is known about its effect on other precursors and metabolites of DHT, as well as on the relationship of these androgens to prostate specific antigen, a marker of prostatic intraepithelial neoplasia. The authors provide new data on the effect of finasteride on precursors and metabolites of DHT. [J Steroid Biochem Mol Biol] Abstract

Expression Analysis of Thrombospondin 2 in Prostate Cancer and Benign Prostatic Hyperplasia
Researchers investigated thrombospondin 2 transcript and protein expression in tumoral and non-tumoral prostate tissues and cell lines, and its implications for prostate cancer diagnosis and progression. [Exp Mol Pathol] Abstract

Phosphodiesterase Type 5 (PDE5) Is Co-Localized with Key Proteins of the Nitric Oxide/Cyclic GMP Signaling in the Human Prostate
Scientists investigated by means of immunohistochemistry in the human prostate the expression and distribution of key mediators of the nitric oxide pathway, namely cyclic GMP, the neuronal nitric oxide synthase, and cyclic GMP-binding protein kinases type I, in relation to PDE5, protein kinase A, and the vasoactive intestinal polypeptide. [World J Urol] Abstract

CLINICAL RESEARCH

Cardiovascular Outcomes in Patients with Locally Advanced and Metastatic Prostate Cancer Treated with Luteinizing-Hormone-Releasing-Hormone Agonists or Transdermal Estrogen: The Randomized, Phase II MRC PATCH Trial (PR09)
In a multicenter, open-label, randomized, Phase II trial, the authors enrolled men with locally advanced or metastatic prostate cancer scheduled to start indefinite hormone therapy. The primary outcome, cardiovascular morbidity and mortality, was analyzed by modified intention to treat and by therapy at the time of the event to account for treatment crossover in cases of disease progression. [Lancet Oncol] Abstract

Initial Management of Prostate-Specific Antigen-Detected, Low-Risk Prostate Cancer and the Risk of Death from Prostate Cancer
Researchers evaluated whether older age in men with low-risk prostate cancer increases the risk of prostate cancer-specific mortality when non-curative approaches are selected as initial management. [BJU Int] Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours

REVIEWS
Roles of MicroRNAs during Prostatic Tumorigenesis and Tumor Progression
The authors focus on the current advances about the role of microRNAs in regulating tumorigenesis and progression of prostate cancer (PCa), mainly in suppressing or promoting PCa growth and metastasis, and maintaining the pluripotency of PCa stem cells. [Oncogene] Abstract
INDUSTRY NEWS

MEDIAN Technologies Announces New €633,000 Study Award
MEDIAN Technologies announced it has been selected to provide imaging solutions and services in a Phase II clinical trial for prostate cancer. [MEDIAN Technologies] Press Release

Columbus CyberKnife Announces Milestones in Prostate Cancer Treatment
Since opening in 2010, Columbus CyberKnife has treated nearly 140 prostate cancer patients with stereotactic body radiation therapy, accounting for 30 percent of the center’s total patients treated. Columbus CyberKnife offers the only CyberKnife® technology available in central Ohio and is one of only three CyberKnife programs in the state. [Vocus PRW Holdings, LLC.] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Gordon Research Conferences: Cell Growth & Proliferation
June 22-23, 2013
West Dover, United States

Visit
our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Genetic and Epigenetic Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Assistant or Associate Professor – Cancer Biology (Yale School of Medicine)

Postdoctoral Position – Advanced Prostate Cancer (Weill Cornell Medical College)

Postdoctoral Position – Aggressiveness or Progression in Prostate Cancer (Roswell Park Cancer Institute)

PhD Studentship – Detection of Novel Prostate Cancer Biomarkers (University of Bath)

PhD Studentship – Multi-Compartment Magnetic Resonance Imaging of Prostate Cancer (University of East Anglia)


Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us